[go: up one dir, main page]

AR014074A1 - Compuesto, nuevo proceso para su produccion, su uso como marcador y un metodo para la valoracion de la pureza o estabilidad a la degradacion de unamuestra de lamotrigina o una dosificacion farmaceutica que comprende lamotrigina - Google Patents

Compuesto, nuevo proceso para su produccion, su uso como marcador y un metodo para la valoracion de la pureza o estabilidad a la degradacion de unamuestra de lamotrigina o una dosificacion farmaceutica que comprende lamotrigina

Info

Publication number
AR014074A1
AR014074A1 ARP990101018A ARP990101018A AR014074A1 AR 014074 A1 AR014074 A1 AR 014074A1 AR P990101018 A ARP990101018 A AR P990101018A AR P990101018 A ARP990101018 A AR P990101018A AR 014074 A1 AR014074 A1 AR 014074A1
Authority
AR
Argentina
Prior art keywords
lamotrigin
marker
purity
production
pharmaceutical dosage
Prior art date
Application number
ARP990101018A
Other languages
English (en)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10833464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR014074(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of AR014074A1 publication Critical patent/AR014074A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe la N-(5-amino-6-(2,3-diclorofenil)-1,2,4-triazina-3-il)-2,3- diclorobenzamida, un nuevo proceso para su produccion, su uso como marcador ymétodo para la valoracion de la pureza o estabilidad a la degradacion de una muestra de lamotrigina o una dosificacion farmacéutica que comprendelamotrigina, valorando dicha muestra a partir de un compuesto seleccionado de 3-amino-6-(2,3-diclorofenil)-1,2,4-triazina-5-(4H)-ona y N-(5-amino-6-(2,3-diclorofenil)-1,2,4-triazina-3-il)-2,3-diclorobenzamida.
ARP990101018A 1998-06-10 1999-03-10 Compuesto, nuevo proceso para su produccion, su uso como marcador y un metodo para la valoracion de la pureza o estabilidad a la degradacion de unamuestra de lamotrigina o una dosificacion farmaceutica que comprende lamotrigina AR014074A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9812413.4A GB9812413D0 (en) 1998-06-10 1998-06-10 Compound and its use

Publications (1)

Publication Number Publication Date
AR014074A1 true AR014074A1 (es) 2001-01-31

Family

ID=10833464

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101018A AR014074A1 (es) 1998-06-10 1999-03-10 Compuesto, nuevo proceso para su produccion, su uso como marcador y un metodo para la valoracion de la pureza o estabilidad a la degradacion de unamuestra de lamotrigina o una dosificacion farmaceutica que comprende lamotrigina

Country Status (31)

Country Link
US (1) US6333198B1 (es)
EP (2) EP0963980B1 (es)
JP (1) JP2989189B1 (es)
KR (1) KR100322354B1 (es)
CN (2) CN1238454A (es)
AP (3) AP9901481A0 (es)
AR (1) AR014074A1 (es)
AT (1) ATE218552T1 (es)
AU (1) AU2031999A (es)
BR (1) BR9900984A (es)
CA (1) CA2265194C (es)
DE (1) DE69901656T2 (es)
DK (1) DK0963980T3 (es)
EA (1) EA000666B1 (es)
ES (1) ES2178342T3 (es)
GB (1) GB9812413D0 (es)
HR (1) HRP990074A2 (es)
HU (1) HUP9900592A3 (es)
ID (1) ID22957A (es)
MA (1) MA24777A1 (es)
NO (2) NO991151L (es)
NZ (1) NZ334590A (es)
PE (1) PE20000332A1 (es)
PL (1) PL331870A1 (es)
PT (1) PT963980E (es)
SG (1) SG85628A1 (es)
SI (1) SI0963980T1 (es)
TR (1) TR199900520A3 (es)
UY (1) UY25946A1 (es)
YU (1) YU12399A (es)
ZA (1) ZA991951B (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055177A1 (en) * 1999-03-10 2002-05-09 Glaxo Wellcome Inc. Compound and its use
WO2001049669A1 (en) * 2000-01-03 2001-07-12 Rpg Life Sciences Limited A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
WO2002053540A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Aspartate derivative of amlodipine as calcium channel antagonist
IL156692A0 (en) 2000-12-29 2004-01-04 Pfizer Ltd Process for making amlodipine maleate
WO2002053541A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Amide derivative of amlodipine
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
EP1309556B1 (en) 2000-12-29 2004-11-24 Pfizer Limited Amlodipine fumarate
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
DE60116514T2 (de) 2000-12-29 2006-08-17 Pfizer Ltd., Sandwich Amlodipinhemimaleat
GB2371862B (en) 2000-12-29 2004-07-14 Bioorg Bv Reference standards for determining the purity or stability of amlodipine maleate and processes therefor
DE10134980C2 (de) 2001-07-17 2003-05-28 Helm Ag Verfahren zur Herstellung von Lamotrigin
CA2366521C (en) 2001-12-24 2007-03-06 Brantford Chemicals Inc. A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
CA2479668A1 (en) * 2002-03-20 2003-10-02 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
HU225667B1 (en) * 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
EP1562912A2 (en) 2003-08-28 2005-08-17 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
US7777034B2 (en) * 2003-11-24 2010-08-17 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
WO2005056534A1 (en) * 2003-12-02 2005-06-23 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
WO2005075427A2 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast sodium polymorphs
US20050187243A1 (en) * 2004-01-30 2005-08-25 Valerie Niddam-Hildesheim Montelukast free acid polymorphs
MD2823G2 (ro) * 2004-02-12 2006-05-31 Институт Химии Академии Наук Молдовы Procedeu de determinare cantitativă a sclareolului în extractele, obţinute din salvia de muscat
CA2563776A1 (en) * 2004-04-21 2005-11-10 Teva Pharmaceutical Industries Ltd. Processes for preparing montelukast sodium
WO2005105768A2 (en) * 2004-04-26 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolic acid and ester derivatives thereof
US20050250773A1 (en) 2004-04-27 2005-11-10 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
DK1761478T3 (da) * 2004-06-28 2008-12-15 Teva Pharm Fine Chemicals Srl En isoleret Atomoxetin urenhed, fremgangsmåde til fremstilling af Atomoxetin urenheder og deres anvendelse som referencestandarder
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
WO2006017357A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
DE602005020014D1 (de) * 2004-07-20 2010-04-29 Teva Gyogyszergyar Zartkoeruen Kristallines mycophenolat-natrium
CN1976894A (zh) * 2004-07-22 2007-06-06 特瓦药物精化学品股份有限公司 阿托莫西汀盐酸盐的多形体
WO2006029253A2 (en) * 2004-09-04 2006-03-16 Teva Pharmaceutical Industries Ltd. A valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
TW200825092A (en) * 2004-09-28 2008-06-16 Teva Pharma A method for reducing the level of AED in atorvastatin calcium sample
US20060128788A1 (en) * 2004-10-19 2006-06-15 Santiago Ini Purification of tegaserod maleate
US7678551B2 (en) * 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
JP2007523213A (ja) * 2004-12-23 2007-08-16 テバ ファーマシューティカル インダストリーズ リミティド 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
CA2591487A1 (en) * 2005-01-11 2006-07-20 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of memantine hydrochloride
KR100945763B1 (ko) * 2005-02-22 2010-03-08 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 제조 방법
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
US7291614B2 (en) 2005-02-24 2007-11-06 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
TW200639161A (en) * 2005-03-14 2006-11-16 Teva Pharma Process for the purification of duloxetine hydrochloride
MX2007010268A (es) * 2005-04-05 2008-02-19 Teva Pharm Fine Chemicals Srl Clorhidrato de atomoxetina estable, un proceso para la preparacion del mismo, y un control analitico de su estabilidad.
CA2603129A1 (en) * 2005-04-06 2006-10-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of pregabalin
US7488846B2 (en) * 2005-04-11 2009-02-10 Teva Pharmaceuical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
US20070066846A1 (en) * 2005-04-11 2007-03-22 Asher Maymon Process for making (S)-Pregabalin
JP2008502707A (ja) * 2005-04-14 2008-01-31 テバ ファーマシューティカル インダストリーズ リミティド クエチアピンフマレートの調製方法
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
EP1879852A1 (en) * 2005-05-10 2008-01-23 Teva Pharmaceutical Industries Ltd Pregabalin free of lactam and a process for preparation thereof
BRPI0605833A (pt) * 2005-05-10 2007-12-18 Teva Pharma pregabalina livre de ácido isobutilglutárico e um processo para sua preparação
CA2604602A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Method for the preparation of pregabalin and salts thereof
MX2007014129A (es) * 2005-05-10 2008-01-11 Teva Pharma Resolucion optica del acido 3-carbamoilmetil-5-metil hexanoico.
WO2006127933A1 (en) 2005-05-23 2006-11-30 Teva Pharmaceutical Industries Ltd. Processes for preparing cinacalcet hydrochloride crystal form i
CN101233100A (zh) * 2005-06-27 2008-07-30 西科尔公司 阿那曲唑中间体的杂质及其应用
WO2007002720A2 (en) * 2005-06-27 2007-01-04 Sicor, Inc. An impurity of anastrozole intermediate, and uses thereof
WO2007005965A1 (en) * 2005-07-05 2007-01-11 Teva Paharmaceutical Industries Ltd. Purification of montelukast
EP1805148A2 (en) * 2005-08-16 2007-07-11 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
US7446220B2 (en) * 2005-09-19 2008-11-04 Teva Pharmaceutical Industries Ltd. Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid
US20070197529A1 (en) * 2005-12-01 2007-08-23 Viviana Braude Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard
WO2007067581A1 (en) 2005-12-05 2007-06-14 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamine)-3-(2-naphthol) thiophene, an impurity of duloxetine hydrochloride
WO2007069264A2 (en) * 2005-12-15 2007-06-21 Alembic Limited Reference standards for determining the purity of telithromycin and processes therefor
US20070203221A1 (en) * 2005-12-27 2007-08-30 Valeriano Merli Processes for preparing darifenacin hydrobromide
WO2007126886A1 (en) * 2006-03-27 2007-11-08 Teva Pharmaceuticals Usa, Inc. Process for preparing memantine hydrochloride substantially free of impurities
US20080146675A1 (en) * 2006-04-05 2008-06-19 Eugenio Castelli Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
GB0609835D0 (en) * 2006-05-18 2006-06-28 Pliva Istrazivanje I Razvoj D Impurities of a pharmaceutical product
WO2007139933A2 (en) * 2006-05-24 2007-12-06 Teva Pharmaceutical Industries Ltd. Processes for the preparation of r-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
BRPI0702897A2 (pt) * 2006-05-31 2011-03-15 Teva Pharmaceutical Ind Ltda processo para preparar um intermediário de pregabalina
WO2007143152A2 (en) * 2006-05-31 2007-12-13 Teva Pharmaceutical Industries Ltd. Preparation of (s)-pregabalin-nitrile
WO2008002665A1 (en) * 2006-06-29 2008-01-03 Teva Pharmaceutical Industries Ltd. Regulation of acid metabolite production
US20120142919A1 (en) * 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
CN101506178A (zh) * 2006-08-14 2009-08-12 隆沙有限公司 制备拉莫三嗪的方法
US20080242877A1 (en) * 2007-02-26 2008-10-02 Vinod Kumar Kansal Intermediates and processes for the synthesis of Ramelteon
WO2008118427A2 (en) * 2007-03-22 2008-10-02 Teva Pharmaceutical Industries Ltd. Synthesis of (s)-(+)-3-(aminomethyl)-5-methyl hexanoic acid
BRPI0803097A2 (pt) * 2007-04-11 2011-11-08 Teva Gyogyszergyar ... método para redução do nìvel de impurezas na fermentação do ácido micofenólico
WO2008151170A2 (en) * 2007-05-31 2008-12-11 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
KR20090101462A (ko) * 2007-10-03 2009-09-28 테바 파마슈티컬 인더스트리즈 리미티드 프레가발린-4-엘리미네이트, 프레가발린 5-엘리미네이트, 기준 마커 및 표준물로서의 이들의 용도, 및 이들을 낮은 수준으로 함유하는 프레가발린의 제조 방법
KR20100058660A (ko) * 2007-10-23 2010-06-03 테바 파마슈티컬 인더스트리즈 리미티드 다사티닙 다형체 및 이의 제조 방법
WO2009056993A2 (en) * 2007-11-01 2009-05-07 Teva Pharmaceutical Industries Ltd. A process for the synthesis of ramelteon and its intermediates
WO2009061513A1 (en) * 2007-11-09 2009-05-14 Thar Pharmaceuticals Crystalline forms of lamotrigine
CA2717580A1 (en) * 2008-03-06 2009-12-17 Teva Pharmaceutical Industries Ltd. Processes for the preparation of o-desmethylvenlafaxine, free from its dimer impurities
KR20100107500A (ko) * 2008-06-23 2010-10-05 테바 파마슈티컬 인더스트리즈 리미티드 (ｓ) 또는 (ｒ)-이소-부틸-글루타릭 에스테르의 입체선택적 효소 합성방법
US20100152468A1 (en) * 2008-10-16 2010-06-17 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
EP2539313A2 (en) * 2010-03-29 2013-01-02 Pliva Hrvatska D.O.O. Crystal forms of o-desmethylvenlafaxine fumarate
WO2012034065A1 (en) 2010-09-09 2012-03-15 Teva Pharmaceutical Industries Ltd. Aliskiren intermediates and a process for analyzing the purity of aliskiren
CN102766104A (zh) * 2012-08-20 2012-11-07 三金集团湖南三金制药有限责任公司 一种治疗双向情感障碍及癫痫病药物拉莫三嗪的合成方法
US10189859B2 (en) 2013-12-21 2019-01-29 Nektar Therapeutics Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
CN110467560B (zh) 2018-05-09 2025-11-25 深圳微芯生物科技股份有限公司 一种苯基氨基丙酸钠衍生物、其制备方法和应用
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
CN113156009B (zh) * 2021-04-20 2023-12-22 三金集团湖南三金制药有限责任公司 高效液相色谱分析拉莫三嗪的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL124029B1 (en) 1979-06-01 1982-12-31 Wellcome Found Process for preparing novel derivatives of 1,2,4-triazine
DE3062603D1 (en) 1979-06-01 1983-05-11 Wellcome Found 3,5-diamino-1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them
GB8613183D0 (en) 1986-05-30 1986-07-02 Wellcome Found Triazine salt
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
AU4311596A (en) * 1994-12-30 1996-07-24 Wellcome Foundation Limited, The Process for the preparation of lamotrigine
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation

Also Published As

Publication number Publication date
JP2000009714A (ja) 2000-01-14
ATE218552T1 (de) 2002-06-15
BR9900984A (pt) 2000-05-02
JP2989189B1 (ja) 1999-12-13
EP0963980A2 (en) 1999-12-15
EP0963980B1 (en) 2002-06-05
EP0963980A3 (en) 2000-05-31
HUP9900592A3 (en) 2002-04-29
YU12399A (sh) 2002-08-12
KR100322354B1 (ko) 2002-02-07
AP2001002286A0 (en) 2001-12-31
MA24777A1 (fr) 1999-10-01
KR20000005611A (ko) 2000-01-25
ID22957A (id) 1999-12-23
CA2265194C (en) 2000-10-10
US6333198B1 (en) 2001-12-25
TR199900520A2 (en) 2000-01-21
HRP990074A2 (en) 2000-10-31
CN1238454A (zh) 1999-12-15
PE20000332A1 (es) 2000-04-10
HUP9900592A2 (hu) 2000-04-28
NZ334590A (en) 2000-07-28
PT963980E (pt) 2002-10-31
ES2178342T3 (es) 2002-12-16
SI0963980T1 (en) 2002-12-31
EA000666B1 (ru) 2000-02-28
DK0963980T3 (da) 2002-09-16
NO991151L (no) 1999-12-13
UY25946A1 (es) 2000-12-29
AP0102286A0 (en) 2000-09-10
SG85628A1 (en) 2002-01-15
DE69901656T2 (de) 2003-01-30
AU2031999A (en) 2000-01-06
NO991151D0 (no) 1999-03-10
HU9900592D0 (en) 1999-04-28
EA199900159A1 (ru) 1999-12-29
TR199900520A3 (tr) 2000-01-21
GB9812413D0 (en) 1998-08-05
EP1170588A1 (en) 2002-01-09
NO20032753D0 (no) 2003-06-17
PL331870A1 (en) 1999-12-20
NO20032753L (no) 1999-12-13
ZA991951B (en) 1999-08-16
DE69901656D1 (de) 2002-07-11
AP9901481A0 (en) 1999-03-31
CN1306210A (zh) 2001-08-01

Similar Documents

Publication Publication Date Title
AR014074A1 (es) Compuesto, nuevo proceso para su produccion, su uso como marcador y un metodo para la valoracion de la pureza o estabilidad a la degradacion de unamuestra de lamotrigina o una dosificacion farmaceutica que comprende lamotrigina
EA200300429A1 (ru) Способ получения порошковых композиций
TR200001603T2 (tr) Yeni bileşikler
ES2162676T3 (es) Derivados de fenileno sustituidos en meta y su uso como antagonistas o inhibidores de integrina alfav,beta3.
CL2004001128A1 (es) Compuestos derivados de halogenopirimidinas aril eter; composicion pesticida; procedimiento de preparacion; compuestos intermediarios; y uso del compuesto como agente pesticida.
ATE170508T1 (de) Bisulfit-additionsverbindungen von argininaldehyden und ihre verwendung als thrombininhibitoren und antikoagulantien
EA200100058A1 (ru) 4-бензилпиперидиналкилсульфоксидные гетероциклические соединения и их применение в качестве подтип-избирательных антагонистов nmda-рецепторов
YU28997A (sh) Cikloalkano-piridini
ES2235311T8 (es) Formulación de budesónida/formoterol para inhalación que tiene una densidad aparente de vertido de 0,30 a 0,36 g/ml, un proceso para preparar la formulación y el uso de la misma.
BR9912109B1 (pt) compostos derivados de quinolina, composições farmacêuticas, processo para a manufatura de um composto, e, uso de um composto.
ES2186227T3 (es) Lapiz magnetico para la concentracion y separacion de particulas.
DE69836678D1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
AR028743A1 (es) DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
ES2148837T3 (es) Procedimiento para la preparacion del 1,4,7,10-tetraaza-ciclododecano y sus derivados.
BR0012622A (pt) Derivados de 3-amino-2-benzil-1-fenil-propano
EA199800675A1 (ru) Дифенилстильбены как пролекарства к ингибиторам циклооксигеназы(сох-2)
AR018879A1 (es) Compuesto de [[4- (2-azido -3-metil -5- oxotetrahidrofuran -2il) -fenil] -hidrazono] propanodinitrilo de aplicacion en el analisis de cargas de levosimendan, preparaciones de referencia para la determinacion de impurezas genotoxicas utilizando dicho compuesto y metodos analiticos para la determinaci
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
EA200101106A1 (ru) Фармацевтический комплекс
UA37217C2 (uk) Аналоги 15-дезоксиспергуаліну, спосіб їх одержання, фармацевтична композиція та проміжні сполуки
EA199900260A1 (ru) Кристаллический фармацевтический продукт
EA200100299A1 (ru) Уреидопиперидиновые производные как селективные антагонисты nk3 - рецепторов человека
ES2147232T3 (es) Uso de compuestos triazinicos como ansioliticos.
AR029149A1 (es) USO DE UN SENSIBILIZADOR DE INSULINA, UNA COMPOSICIoN FARMACÉUTICA Y UN MÉTODO PARA DETERMINAR LA CONCENTRACIoN PLASMA TICA UMBRAL PARA UN COMPUESTO ANTIDIABÉTICO.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal